Akèy › Gliyoblastòm › New York › New York City
Etid klinik pou Gliyoblastòm nan New York City, NY
30 etid pou Gliyoblastòm ap chèche patisipan nan sit nan ak bò kote New York City (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
Ap rekriteFaz 3
- Weill Cornell Medicine, New York
- NewYork-Presbyterian / Columbia University Irving Medical Center, New York
- Lennox Hill Hospital, New York
Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
Ap rekriteFaz 2
- New York University Langone's Perlmutter Cancer Institute, New York
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
Ap rekriteFaz 1/2
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Ap rekriteFaz 2/3
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University Medical Center, New York
- Memorial Sloan Kettering Cancer Center*, New York
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Ap rekriteFaz 2
- Columbia University Irving Medical Center, New York
A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM
Ap rekriteFaz 1
- Lenox Hill Hospital, New York
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Ap rekriteFaz 1/2
- New York University Langone Medical Center, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial
Ap rekriteFaz 1
- Memorial Sloan Kettering Cancer Center, New York
Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma
Ap rekriteFaz 3
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
Ap rekriteFaz 1/2
- Icahn School of Medicine at Mount Sinai - Oncology, New York
- Memorial Sloan Kettering Cancer Center New York - Main Campus, New York
Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma
Ap rekriteFaz 1
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
Ap rekriteFaz 1
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Ap rekriteFaz 3
- NYU Langone Health, New York
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University Medical Center, New York
- ak 1 plis
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
Ap rekriteFaz 2
- Memorial Sloan Kettering Cancer Center, New York
A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma
Ap rekriteFaz 1
- NYU Langone Health, New York
Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma
Ap rekrite
- NYU Langone Health, New York
Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma
Ap rekriteFaz 2
- New York Langone, New York
- Columbia University, New York
- Memorial Sloan Kettering Cancer Center, New York
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
Ap rekriteFaz 2
- Lenox Hill Hospital, New York
A Study of 177Lu-PSMA-617 in People With Gliomas
Ap rekriteFaz 1
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
Ap rekriteFaz 1/2
- Lenox Hill Brain Tumor Center, New York
Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
Ap rekriteFaz 3
- Lenox Hill Brain Tumor Center, New York
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
Ap rekriteFaz 1/2
- Lenox Hill Brain Tumor Center, New York
Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma
Ap rekrite
- Lenox Hill Brain Tumor Center, New York
Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)
Ap rekrite
- Lenox Hill Brain Tumor Center, New York
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
Ap rekriteFaz 1/2
- Lenox Hill Brain Tumor Center, New York
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Ap rekriteFaz 1/2
- NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
Ap rekriteFaz 2
- Lenox Hill Brain Tumor Center, New York
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
Ap rekriteFaz 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, New York
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
Ap rekriteFaz 1
- Columbia University Medical Center - Herbert Irving Pavilion, New York
Etid Gliyoblastòm nan lòt vil
- Boston, MA28 etid
- Houston, TX26 etid
- Los Angeles, CA24 etid
- Durham, NC20 etid
- San Francisco, CA17 etid
- Chicago, IL15 etid
- Washington, DC15 etid
- Miami, FL14 etid
- Columbus, OH14 etid
- Rochester, MN13 etid
- Jacksonville, FL13 etid
- Aurora, CO12 etid
Lòt etid nan New York City
- Kansè nan tete136 etid
- Kansè Poumon ki pa ti selil121 etid
- Kansè (tout kalite)109 etid
- Kansè pwostat103 etid
- Kansè Metastatik93 etid
- Kansè kolorektal78 etid
- Kansè ovè69 etid
- Kansè poumon60 etid
- Myelom Miltip60 etid
- Kansè pankreyas60 etid
- Kansè Endomèt52 etid
- Leksemi mieloïd egi51 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.